



EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	4173	((544/363) or (549/496) or (560/153) or (514/253.08,471,550)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/09/20 07:30



chain nodes :

1 2 3 5 6 7 8 9 10 11 12 22 23 24 25 28 30

ring nodes :

14 15 16 17 18 19

chain bonds :

1-2 1-3 1-22 3-5 5-6 5-23 6-7 6-8 8-9 9-10 10-11 10-12 12-15 23-24 24-25 28-30

ring bonds :

14-15 14-19 15-16 16-17 17-18 18-19

exact/norm bonds :

1-2 1-3 3-5 6-7 6-8 8-9 10-11 10-12 12-15 23-24 24-25 28-30

exact bonds :

1-22 5-6 5-23 9-10

normalized bonds :

14-15 14-19 15-16 16-17 17-18 18-19

isolated ring systems :

containing 14 :

G1:O,S,N



Match level :

1:CLASS2:CLASS3:CLASS5:CLASS6:CLASS7:CLASS8:CLASS9:CLASS10:CLASS11:CLASS12:CLASS14:Atom 15:Atom 16:CLASS17:CLASS18:Atom 19:Atom 22:CLASS23:CLASS24:CLASS25:CLASS28:CLASS29:Atom 30:CLASS

10/511,489

=>

Uploading C:\Program Files\Stnexp\Queries\10511489 (e).str



chain nodes :

1 2 3 5 6 7 8 9 10 11 12 22 23 24 25 28 30

ring nodes :

14 15 16 17 18 19

chain bonds :

1-2 1-3 1-22 3-5 5-6 5-23 6-7 6-8 8-9 9-10 10-11 10-12 12-15 23-24
24-25 28-30

ring bonds :

14-15 14-19 15-16 16-17 17-18 18-19

exact/norm bonds :

1-2 1-3 3-5 6-7 6-8 8-9 10-11 10-12 12-15 23-24 24-25 28-30

exact bonds :

1-22 5-6 5-23 9-10

normalized bonds :

14-15 14-19 15-16 16-17 17-18 18-19

isolated ring systems :

containing 14 :

G1:O,S,N

Match level :

1:CLASS 2:CLASS 3:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS

11:CLASS 12:CLASS 14:Atom 15:Atom 16:CLASS 17:CLASS 18:Atom 19:Atom

22:CLASS 23:CLASS 24:CLASS 25:CLASS 28:CLASS 29:Atom 30:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

10/511,489

L1 STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.



=> s l1 sss sam
SAMPLE SEARCH INITIATED 06:21:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 83331 TO ITERATE

2.4% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 1649457 TO 1683783
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=>
Uploading C:\Program Files\Stnexp\Queries\10511489 (f).str



chain nodes :
1 2 3 5 6 7 8 9 10 11 12 22 23 24 25 28 30
ring nodes :
14 15 16 17 18 19
chain bonds :
1-2 1-3 1-22 3-5 5-6 5-23 6-7 6-8 8-9 9-10 10-11 10-12 12-15 23-24
24-25 28-30
ring bonds :
14-15 14-19 15-16 16-17 17-18 18-19
exact/norm bonds :
1-2 1-3 3-5 6-7 6-8 8-9 10-11 10-12 12-15 23-24 24-25 28-30
exact bonds :

10/511,489

1-22 5-6 5-23 9-10
normalized bonds :
14-15 14-19 15-16 16-17 17-18 18-19
isolated ring systems :
containing 14 :

G1:O,S,N

Match level :

1:CLASS 2:CLASS 3:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 14:Atom 15:Atom 16:CLASS 17:CLASS 18:Atom 19:Atom
22:CLASS 23:CLASS 24:CLASS 25:CLASS 28:CLASS 29:Atom 30:CLASS

L3 STRUCTURE UPLOADED

=> d 13

L3 HAS NO ANSWERS

L3 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> s 13 sss sam

SAMPLE SEARCH INITIATED 06:23:53 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 12177 TO ITERATE

16.4% PROCESSED 2000 ITERATIONS

0 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**



PROJECTED ITERATIONS: 236928 TO 250152

PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L3

=>

Uploading C:\Program Files\Stnexp\Queries\10511489 (g).str



```

chain nodes :
1  2  3  5  6  7  8  9 10 11 12 22 23 24 25 28 30
ring nodes :
14 15 16 17 18 19
chain bonds :
1-2 1-3 1-22 3-5 5-6 5-23 6-7 6-8 8-9 9-10 10-11 10-12 12-15 23-24
24-25 28-30
ring bonds :
14-15 14-19 15-16 16-17 17-18 18-19
exact/norm bonds :
1-2 1-3 3-5 6-7 6-8 8-9 10-11 10-12 12-15 23-24 24-25 28-30
exact bonds :
1-22 5-6 5-23 9-10
normalized bonds :
14-15 14-19 15-16 16-17 17-18 18-19
isolated ring systems :
containing 14 :

```

G1:O,S,N

Match level :

```

1:CLASS 2:CLASS 3:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 14:Atom 15:Atom 16:CLASS 17:CLASS 18:Atom 19:Atom
22:CLASS 23:CLASS 24:CLASS 25:CLASS 28:CLASS 29:Atom 30:CLASS

```

L5 STRUCTURE UPLOADED

=> d 15

L5 HAS NO ANSWERS

L5 STR

10/511,489

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> s 15 sss sam

SAMPLE SEARCH INITIATED 06:26:17 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 74935 TO ITERATE

2.7% PROCESSED 2000 ITERATIONS

0 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**

PROJECTED ITERATIONS: 1482410 TO 1514990

PROJECTED ANSWERS: 0 TO 0

L6 0 SEA SSS SAM L5

=> s 13 sss ful

FULL SEARCH INITIATED 06:28:26 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 243566 TO ITERATE

100.0% PROCESSED 243566 ITERATIONS

10 ANSWERS

SEARCH TIME: 00.00.04

L7 10 SEA SSS FUL L3

=> => s 17

L8 2 L7

=> d 18 1-2 bib,ab,hitstr

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:855762 CAPLUS
 DN 139:354460
 TI Peptide deformylase activated prodrugs
 IN Sergeeva, Maria V.; Doppalapudi, Venkata Ramana
 PA Newbiotics, Inc., USA; Celmed Oncology (USA), Inc.
 SO PCT Int. Appl., 58 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003088913	A2	20031030	WO 2003-US11981	20030417
	WO 2003088913	A3	20040401		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, RO, SE, SI, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2482029	A1	20031030	CA 2003-2482029	20030417
	AU 2003225047	A1	20031103	AU 2003-225047	20030417
	EP 1499318	A2	20050126	EP 2003-721752	20030417
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2005096254	A1	20050505	US 2003-511489	20030417
	CN 1662238	A	20050831	CN 2003-813847	20030417
	JP 2006507219	T	20060302	JP 2003-585666	20030417
	BR 2003009418	A	20070306	BR 2003-9418	20030417
	MX 2004PA10230	A	20050608	MX 2004-PA10230	20041015
PRAI	US 2002-374089P	P	20020418		
	WO 2003-US11981	W	20030417		

OS MARPAT 139:354460

AB This invention provides a method for inhibiting the growth of a microorganism that expresses Peptide Deformylase by contacting the microorganism with an effective amount of the compound described herein. This method inhibits the growth of gram-pos. and gram-neg. microorganism, e.g., *S. aureus*, *S. epidermidis*, *K. pneumoniae*, *E. aerogenes*, and *E. cloacae*. This method can be practiced in vitro, ex vivo and in vivo. Further provided is a method for alleviating the symptoms of an infection by a Peptide Deformylase expressing microorganism in a subject by administering or delivering to the subject an effective amount of the compound described above.


IT 474780-84-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (peptide deformylase activated prodrugs for inhibiting growth of microorganism)

RN 474780-84-2 CAPLUS

CN L-Leucine, N-formyl-L-methionyl-, 4-(hydroxymethyl)phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 474877-34-4P, NB 3024 474877-35-5P, NB 3057

474877-36-6P, NB 3068 474877-37-7P, NB 3103


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prodrug; peptide deformylase activated prodrugs for inhibiting growth of microorganism)

RN 474877-34-4 CAPLUS

CN L-Leucine, N-formyl-L-methionyl-, 4-[[[1-oxido-2-pyridinyl]thio]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 474877-35-5 CAPLUS

CN L-Leucine, N-formyl-L-methionyl-, 4-[[[1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinyl]carbonyl]oxy]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


 —SMe


RN 474877-36-6 CAPLUS

CN L-Leucine, N-formyl-L-methionyl-, 4-[[[4-(3-carboxy-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-quinolinyl)-1-piperazinyl]carbonyl]oxy]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 474877-37-7 CAPLUS

CN L-Leucine, N-formyl-L-methionyl-, 4-[[[bis(2-chloroethyl)amino]carbonyl]oxy]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 618443-15-5P, NB 3144 618443-16-6P, NB 3145
618443-17-7P, NB 3162 618443-18-8P, NB 3165
618443-19-9P, NB 3177

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prodrugs from; peptide deformylase activated prodrugs for inhibiting growth of microorganism)

RN 618443-15-5 CAPLUS

CN L-Leucine, N-formyl-L-methionyl-, 2,6-dibromo-4-(hydroxymethyl)phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 618443-16-6 CAPLUS

CN L-Leucine, N-formyl-L-methionyl-, 5'-(hydroxymethyl)[1,1':3',1''-terphenyl]-2'-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 618443-17-7 CAPLUS

CN L-Leucine, N-formyl-L-methionyl-, 2-bromo-4-(hydroxymethyl)-6-methoxyphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 618443-18-8 CAPLUS

CN L-Leucine, N-formyl-L-methionyl-, 4-(hydroxymethyl)-2,6-dimethylphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 618443-19-9 CAPLUS

CN L-Leucine, N-formyl-L-methionyl-, 2-bromo-6-(2-furanyl)-4-(hydroxymethyl)phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/511,489



L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2002:868689 CAPLUS
 DN 137:358150
 TI Peptide deformylase activated prodrugs
 IN Sergeeva, Maria Vladimir; Doppalapudi, Venkata Ramana
 PA Newbiotics, Inc., USA
 SO PCT Int. Appl., 60 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

*Same Inv
Entity*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002089739	A2	20021114	WO 2002-US14500	20020509
	WO 2002089739	A3	20030821		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2447470	A1	20021114	CA 2002-2447470	20020509
	AU 2002314773	A1	20021118	AU 2002-314773	20020509
	US 2003091587	A1	20030515	US 2002-142089	20020509
	US 7163923	B2	20070116		
	EP 1399467	A2	20040324	EP 2002-741696	20020509
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002010149	A	20040629	BR 2002-10149	20020509
	JP 2005505502	T	20050224	JP 2002-586878	20020509
PRAI	US 2001-290099P	P	20010509		
	WO 2002-US14500	W	20020509		

OS MARPAT 137:358150

AB This invention provides a method for inhibiting the growth of a microorganism that expresses Peptide Deformylase by contacting the microorganism with an effective amount of the compound described herein. This method inhibits the growth of gram-pos. and gram-neg. microorganism, e.g., *S. aureus*, *S. epidermidis*, *K. pneumoniae*, *E. aerogenes*, *E. cloacae*, *M. catarrhalis*, *E. coli*, *E. faecalis*, *H. influenzae* and *P. aeruginosa*. This method can be practiced in vitro, ex vivo and in vivo. Further provided is a method for alleviating the symptoms of an infection by a Peptide Deformylase-expressing microorganism in a subject by administering or delivering to the subject an effective amount of the compound described above.

IT 474877-35-5P, NB 3057 474877-36-6P, NB 3068
 474877-37-7P, NB 3103

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(peptide deformylase activated prodrugs for inhibiting growth of microorganism)

RN 474877-35-5 CAPLUS

CN L-Leucine, N-formyl-L-methionyl-, 4-[[[1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinyl]carbonyl]oxy]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


SMe


RN 474877-36-6 CAPLUS

CN L-Leucine, N-formyl-L-methionyl-, 4-[[[4-(3-carboxy-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-quinolinyl)-1-piperazinyl]carbonyl]oxy]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 474877-37-7 CAPLUS

CN L-Leucine, N-formyl-L-methionyl-, 4-[[[bis(2-chloroethyl)amino]carbonyl]oxy]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 474877-34-4P, NB 3024


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(peptide deformylase activated prodrugs for inhibiting growth of microorganism)

RN 474877-34-4 CAPLUS

CN L-Leucine, N-formyl-L-methionyl-, 4-[[[1-oxido-2-pyridinyl]thio]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 474780-84-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(peptide deformylase activated prodrugs for inhibiting growth of
microorganism)

RN 474780-84-2 CAPLUS

CN L-Leucine, N-formyl-L-methionyl-, 4-(hydroxymethyl)phenyl ester (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



10/511,489

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

11.48

189.19

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY


SESSION

CA SUBSCRIBER PRICE

-1.56

-1.56

STN INTERNATIONAL LOGOFF AT 06:29:47 ON 20 SEP 2007



chain nodes :

1 2 3 5 6 7 8 9 10 11 21 22 24 25 26 27 32 34 35 36 37 38 41

ring nodes :

14 15 16 17 18 19

ring/chain nodes :

12

chain bonds :

1-2 1-3 3-5 5-6 6-7 6-8 8-9 9-10 10-11 10-12 12-15 21-34 22-24 22-41 24-25 25-26 25-27 35-36 37-38

ring bonds :

14-15 14-19 15-16 16-17 17-18 18-19

exact/norm bonds :

1-2 1-3 3-5 6-7 6-8 8-9 10-11 10-12 12-15 21-34 22-24 24-25 25-26 25-27 35-36 37-38

exact bonds :

5-6 9-10 22-41

normalized bonds :

14-15 14-19 15-16 16-17 17-18 18-19

isolated ring systems :

containing 14 :

G1:O,S

G2:[*1],[*2],[*3],[*4]

Match level :

1:CLASS2:CLASS3:CLASS5:CLASS6:CLASS7:CLASS8:CLASS9:CLASS10:CLASS11:CLASS12:CLASS14:Atom 15:Atom 16:CLASS17:CLASS18:Atom 19:Atom 21:CLASS22:CLASS24:CLASS25:CLASS26:CLASS27:Atom 32:CLASS33:Atom 34:Atom

35:CLASS36:Atom 37:CLASS38:Atom 41:CLASS

10/511,489

=>.....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1839


L1 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L2 SCREEN CREATED

=>

Uploading C:\Program Files\Stnexp\Queries\10511489 (b).str



chain nodes :

1 2 3 5 6 7 8 9 10 11 27 28 30 31 32 33 39

ring nodes :

14 15 16 17 18 19 21 22 23 24 25 26

ring/chain nodes :

12

chain bonds :

1-2 1-3 3-5 5-6 6-7 6-8 8-9 9-10 10-11 10-12 12-15 22-27 28-30 30-31
31-32 31-33

ring bonds :

14-15 14-19 15-16 16-17 17-18 18-19 21-22 21-26 22-23 23-24 24-25 25-26

exact/norm bonds :

1-2 1-3 3-5 6-7 6-8 8-9 10-11 10-12 12-15 22-27 28-30 30-31 31-32
31-33

exact bonds :

5-6 9-10

10/511,489

normalized bonds :
14-15 14-19 15-16 16-17 17-18 18-19 21-22 21-26 22-23 23-24 24-25 25-26
isolated ring systems :
containing 14 : 21 :

G1:O,S

G2:[*1],[*2]

Match level :

1:CLASS 2:CLASS 3:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 14:Atom 15:Atom 16:CLASS 17:CLASS 18:Atom 19:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:CLASS 28:CLASS 30:CLASS
31:CLASS 32:CLASS 33:Atom 39:CLASS 40:Atom

L3 STRUCTURE UPLOADED

=> que L3 AND L1 NOT L2

L4 QUE L3 AND L1 NOT L2

=> d l4

L4 HAS NO ANSWERS

L1 SCR 1839

L2 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L3 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L4 QUE L3 AND L1 NOT L2

=> s l4 sss sam

SAMPLE SEARCH INITIATED 18:32:03 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 604 TO ITERATE

100.0% PROCESSED 604 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**


PROJECTED ITERATIONS: 10606 TO 13554

PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L3 AND L1 NOT L2

=>

Uploading C:\Program Files\Stnexp\Queries\10511489 (c).str



chain nodes :

1 2 3 5 6 7 8 9 10 11 21 22 24 25 26 27 33 35 36 37 38 39

ring nodes :

14 15 16 17 18 19

ring/chain nodes :

12

chain bonds :

1-2 1-3 3-5 5-6 6-7 6-8 8-9 9-10 10-11 10-12 12-15 21-35 22-24 24-25
25-26 25-27 36-37 38-39

ring bonds :

14-15 14-19 15-16 16-17 17-18 18-19

exact/norm bonds :

1-2 1-3 3-5 6-7 6-8 8-9 10-11 10-12 12-15 21-35 22-24 24-25 25-26
25-27 36-37 38-39

exact bonds :

5-6 9-10

normalized bonds :

14-15 14-19 15-16 16-17 17-18 18-19

isolated ring systems :

containing 14 :

G1:O,S

G2:[*1],[*2],[*3],[*4]

Match level :

1:CLASS 2:CLASS 3:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 14:Atom 15:Atom 16:CLASS 17:CLASS 18:Atom 19:Atom
21:CLASS 22:CLASS 24:CLASS 25:CLASS 26:CLASS 27:Atom 33:CLASS 34:Atom
35:Atom 36:CLASS 37:Atom 38:CLASS 39:Atom

L6 STRUCTURE UPLOADED

=> d 16

L6 HAS NO ANSWERS

L6 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 16 sss sam

SAMPLE SEARCH INITIATED 18:34:58 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 811 TO ITERATE

100.0% PROCESSED 811 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**


PROJECTED ITERATIONS: 14512 TO 17928

PROJECTED ANSWERS: 0 TO 0

L7 0 SEA SSS SAM L6

=>

Uploading C:\Program Files\Stnexp\Queries\10511489 (d).str




```

chain nodes :
1  2  3  5  6  7  8  9 10 11 21 22 24 25 26 27 32 34 35 36 37 38 41
ring nodes :
14 15 16 17 18 19
ring/chain nodes :
12
chain bonds :
1-2 1-3 3-5 5-6 6-7 6-8 8-9 9-10 10-11 10-12 12-15 21-34 22-24 22-41
24-25 25-26 25-27 35-36 37-38
ring bonds :
14-15 14-19 15-16 16-17 17-18 18-19
exact/norm bonds :
1-2 1-3 3-5 6-7 6-8 8-9 10-11 10-12 12-15 21-34 22-24 24-25 25-26
25-27 35-36 37-38
exact bonds :
5-6 9-10 22-41
normalized bonds :
14-15 14-19 15-16 16-17 17-18 18-19
isolated ring systems :
containing 14 :

```

G1:O,S

G2:[*1],[*2],[*3],[*4]

Match level :

```

1:CLASS 2:CLASS 3:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 14:Atom 15:Atom 16:CLASS 17:CLASS 18:Atom 19:Atom
21:CLASS 22:CLASS 24:CLASS 25:CLASS 26:CLASS 27:Atom 32:CLASS 33:Atom
34:Atom 35:CLASS 36:Atom 37:CLASS 38:Atom 41:CLASS

```

L8 STRUCTURE UPLOADED

=> d 18

L8 HAS NO ANSWERS

L8 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 18 sss sam

SAMPLE SEARCH INITIATED 18:37:21 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 811 TO ITERATE

100.0% PROCESSED 811 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**

PROJECTED ITERATIONS: 14512 TO 17928

PROJECTED ANSWERS: 0 TO 0

L9 0 SEA SSS SAM L8

10/511,489

=> s l8 sss ful
FULL SEARCH INITIATED 18:37:41 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 15839 TO ITERATE

100.0% PROCESSED 15839 ITERATIONS
SEARCH TIME: 00.00.02

5 ANSWERS

L10 5 SEA SSS FUL L8

=> => s l10
L11 3 L10

=> d l11 1-3 bib,ab,hitstr

L11 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:855762 CAPLUS
 DN 139:354460
 TI Peptide deformylase activated prodrugs
 IN Sergeeva, Maria V.; Doppalapudi, Venkata Ramana
 PA Newbiotics, Inc., USA; Celmed Oncology (USA), Inc.
 SO PCT Int. Appl., 58 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

Appl

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003088913	A2	20031030	WO 2003-US11981	20030417
	WO 2003088913	A3	20040401		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, RO, SE, SI, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2482029	A1	20031030	CA 2003-2482029	20030417
	AU 2003225047	A1	20031103	AU 2003-225047	20030417
	EP 1499318	A2	20050126	EP 2003-721752	20030417
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2005096254	A1	20050505	US 2003-511489	20030417
	CN 1662238	A	20050831	CN 2003-813847	20030417
	JP 2006507219	T	20060302	JP 2003-585666	20030417
	BR 2003009418	A	20070306	BR 2003-9418	20030417
	MX 2004PA10230	A	20050608	MX 2004-PA10230	20041015
PRAI	US 2002-374089P	P	20020418		
	WO 2003-US11981	W	20030417		

OS MARPAT 139:354460

AB This invention provides a method for inhibiting the growth of a microorganism that expresses Peptide Deformylase by contacting the microorganism with an effective amount of the compound described herein. This method inhibits the growth of gram-pos. and gram-neg. microorganism, e.g., *S. aureus*, *S. epidermidis*, *K. pneumoniae*, *E. aerogenes*, and *E. cloacae*. This method can be practiced in vitro, ex vivo and in vivo. Further provided is a method for alleviating the symptoms of an infection by a Peptide Deformylase expressing microorganism in a subject by administering or delivering to the subject an effective amount of the compound described above.

IT 474877-34-4P, NB 3024 474877-35-5P, NB 3057
 474877-36-6P, NB 3068


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prodrug; peptide deformylase activated prodrugs for inhibiting growth of microorganism)

RN 474877-34-4 CAPLUS

CN L-Leucine, N-formyl-L-methionyl-, 4-[[[1-oxido-2-pyridinyl]thio]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 474877-35-5 CAPLUS

CN L-Leucine, N-formyl-L-methionyl-, 4-[[[1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinyl]carbonyl]oxy]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


— SMe

RN 474877-36-6 CAPLUS


CN L-Leucine, N-formyl-L-methionyl-, 4-[[[4-(3-carboxy-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-quinolinyl)-1-piperazinyl]carbonyl]oxy]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 474877-33-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prodrugs; peptide deformylase activated prodrugs for inhibiting growth of microorganism)

RN 474877-33-3 CAPLUS

CN L-Leucine, N-formyl-L-methionyl-, 5-chloro-2-(2,4-dichlorophenoxy)phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2002:868689 CAPLUS
 DN 137:358150
 TI Peptide deformylase activated prodrugs
 IN Sergeeva, Maria Vladimир; Doppalapudi, Venkata Ramana
 PA Newbiotics, Inc., USA
 SO PCT Int. Appl., 60 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

Same Inv.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002089739	A2	20021114	WO 2002-US14500	20020509
	WO 2002089739	A3	20030821		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2447470	A1	20021114	CA 2002-2447470	20020509
	AU 2002314773	A1	20021118	AU 2002-314773	20020509
	US 2003091587	A1	20030515	US 2002-142089	20020509
	US 7163923	B2	20070116		
	EP 1399467	A2	20040324	EP 2002-741696	20020509
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	BR 2002010149	A	20040629	BR 2002-10149	20020509
	JP 2005505502	T	20050224	JP 2002-586878	20020509
PRAI	US 2001-290099P	P	20010509		
	WO 2002-US14500	W	20020509		

OS MARPAT 137:358150

AB This invention provides a method for inhibiting the growth of a microorganism that expresses Peptide Deformylase by contacting the microorganism with an effective amount of the compound described herein. This method inhibits the growth of gram-pos. and gram-neg. microorganism, e.g., *S. aureus*, *S. epidermidis*, *K. pneumoniae*, *E. aerogenes*, *E. cloacae*, *M. catarrhalis*, *E. coli*, *E. faecalis*, *H. influenzae* and *P. aeruginosa*. This method can be practiced in vitro, ex vivo and in vivo. Further provided is a method for alleviating the symptoms of an infection by a Peptide Deformylase-expressing microorganism in a subject by administering or delivering to the subject an effective amount of the compound described above.

IT 474877-33-3P, NB 2046 474877-35-5P, NB 3057

474877-36-6P, NB 3068


RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(peptide deformylase activated prodrugs for inhibiting growth of microorganism)

RN 474877-33-3 CAPLUS

CN L-Leucine, N-formyl-L-methionyl-, 5-chloro-2-(2,4-dichlorophenoxy)phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 474877-35-5 CAPLUS

CN L-Leucine, N-formyl-L-methionyl-, 4-[[[1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinyl]carbonyl]oxy]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


— SMe

RN 474877-36-6 CAPLUS


CN L-Leucine, N-formyl-L-methionyl-, 4-[[[4-(3-carboxy-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-quinolinyl)-1-piperazinyl]carbonyl]oxy]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 474877-34-4P, NB 3024

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(peptide deformylase activated prodrugs for inhibiting growth of microorganism)

RN 474877-34-4 CAPLUS

CN L-Leucine, N-formyl-L-methionyl-, 4-[[[1-oxido-2-pyridinyl)thio]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/511,489



L11 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1982:104773 CAPLUS
 DN 96:104773
 TI Amino acid and peptide ester of leucoindooanilines and an agent containing
 this compound for determining a proteolytic enzyme
 IN Berger, Dieter; Braun, Franz; Frey, Guenter; Knappe, Wolfgang Reinhold;
 Kuhr, Manfred; Werner, Wolfgang
 PA Boehringer Mannheim G.m.b.H. , Fed. Rep. Ger.
 SO Ger. Offen., 60 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3005845	A1	19810903	DE 1980-3005845	19800216
	US 4469789	A	19840904	US 1981-229205	19810128
	EP 34323	A2	19810826	EP 1981-100909	19810210
	EP 34323	A3	19811230		
	EP 34323	B1	19830817		
	R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	AT 4453	T	19830915	AT 1981-100909	19810210
	JP 56138153	A	19811028	JP 1981-20251	19810216
	JP 02051900	B	19901108		
PRAI	DE 1980-3005845	A	19800216		
	EP 1981-100909	A	19810210		

AB Title esters I [X = amino acid or peptide residue; R = N-protective group; R1, R2, R3, R4 = H, perhaloalkyl, alkoxy, aralkoxy, acylamino, acylalkenyl, OH, alkylmercapto, alkylsulfonyl, COR11 (R11 = OH, alkoxy, aralkoxy, NH2, alkylamino); R5, R6, R7, R8 = H, halo, perhaloalkyl, alkoxy, aralkoxy, OH, NO2; R9, R10 = H, alkyl, hydroxyalkyl; R9R10 = alkylene, alkyleneoxyalkylene] were prepared as substrates for proteolytic enzymes. The determination of proteinases or esterases can be achieved by enzymically cleaving I to the corresponding phenols II, which can be oxidized to the colored cyclohexadienones III. Thus, Tos-Ala-OH (Tos = tosyl) was treated SOCl2 to give the acid chloride, which was esterified with 4-hydroxy-4'-(dimethylamino)diphenylamine to give 13.6% ester IV. A solution of 45.3 mg IV in 100 mL acetone was used for enzyme determination of leukocyte-containing urine.

IT 80898-53-9P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 80898-53-9 CAPLUS

CN L-Alanine, N-[N-[N-[(4-methylphenyl)sulfonyl]-L-alanyl]-L-alanyl]-, 4-[[4-(dimethylamino)phenyl]amino]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





10/511,489

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

16.28

193.09

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-2.34

-2.34

STN INTERNATIONAL LOGOFF AT 18:38:31 ON 19 SEP 2007